David, We sure hope your right, yet not only ISSM, but with INCE, I was technologies being acquired and sold, assets moved from shells to shells, captive investors along the way, always great stories & hot technology. But having lost so much on these OTC's (ISSM, INCE, QDRX, SEXI, IAPI, OLEX) I've sworn off OTC's. The only developmental stage companies I'll touch are biotechs with several promising therapies in at least phase II clinical studies, and good technology validation. Scott
Hope this works out well for you. This actually has the potential to be a curse for us - it's still trading, so we can't write it off. |
